Categories: NewsPharmaceutical

Diana Shuster, PhD, Joins CenExel as Vice President of Clinical Sciences

SALT LAKE CITY, UT / ACCESSWIRE / January 30, 2024 / CenExel, a leading clinical research organization, is thrilled to announce the appointment of Diana Shuster, PhD, as the new Vice President of Clinical Sciences. In her role, Dr. Shuster will bring her extensive expertise in Early Phase and Translational medicine to lead and advance clinical development initiatives at CenExel.

Diana Shuster

Dr. Shuster, a clinical pharmacologist, has a rich background in the pharmaceutical industry, having worked across various sectors including midsize and big pharma. Her experience includes notable contributions to companies such as Seattle Genetics, AbbVie, PRA Health Sciences/ICON, and most recently, Recursion, where she served as the clinical pharmacology lead for several compounds in clinical development, as well as the project team lead for a rare disease compound in Phase 2 development.

CenExel Chief Executive Officer Stuart Goldblatt expressed his excitement about Dr. Shuster joining the team, stating, “We are thrilled to welcome Dr. Shuster to CenExel. Her impressive background in Early Phase and Translational medicine, coupled with her extensive experience in leading clinical pharmacology strategy, makes her a valuable addition to our leadership team. We look forward to leveraging her skills to drive innovation and growth within our organization.”

Dr. Shuster herself expressed her enthusiasm about joining CenExel, saying, “I am incredibly excited to join CenExel and contribute to the trailblazing work they are doing in clinical research. The commitment to excellence, innovation, and collaboration at CenExel aligns perfectly with my own values. I look forward to being a part of this team and contributing to the advancement of medical innovations.”

In addition to her professional achievements, Dr. Shuster is a lifelong learner, highly motivated by acquiring new knowledge. She values ownership, excellence, and the camaraderie of a great team. Known for her approachability, she encourages others to come to her with any questions, fostering a collaborative and supportive environment.

Dr. Shuster is excited about the opportunity to contribute to the vision of CenExel and looks forward to collaborating with the entire team.

Contact Information

Sara Koeblin
Director of Corporate Communications
s.koeblin@cenexel.com
(617) 639-6075

SOURCE: CenExel

View the original press release on newswire.com.

Staff

Recent Posts

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

56 minutes ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

57 minutes ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

57 minutes ago

How to Choose a Plastic Surgeon in 2026: Dr. Meegan Gruber, MD, PhD Releases a Tampa Bay Patient Safety Checklist

Board-certified plastic surgeon shares a practical, question-based guide to help patients verify credentials, facility standards,…

57 minutes ago

Facelift + Eyelid Surgery in Tampa: Gruber Plastic Surgery Shares 2025 Planning Insights on Natural Results and Popular Procedure Pairings

ASPS trend reporting highlights facelift combined with eyelid surgery as a leading 2025 combination; national…

57 minutes ago

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…

4 hours ago